References
- Global Strategy for Asthma Management and Prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 1995, Publication No. 95–3659
- Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, Ishida S, Hiwada K. Circulating inter-leukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med 1995; 153: 1354
- Taylor I K. Cysteinyl leukotrienes in asthma: Current state of therapeutic evaluation. Thorax 1995; 50: 1005
- Pauwels R A, Joos G F, Kips J C. Leukotrienes as therapeutic target in asthma. Allergy 1995; 50: 615
- Ford-Hutchinson A W. Leukotriene antagonists and inhibitors: Clinical applications. Adv Prostaglandins Thromboxane Leukotriene Res 1995; 23: 69
- Dahlen B, Dahlen S-E. Leukotrienes as mediators of airway obstruction and inflammation in asthma. Clin Exp Allergy 1995; 25: 50
- Yamaguchi T, Kohrogi H, Honda I, Kawano O, Sugimoto M, Araki S, Ando M. A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotriene C4 and D4 and antigen in vitro. Am Rev Respir Dis 1992; 146: 923
- Taniguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, Takishima T. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92: 507
- Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87: 133
- Yamnmoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254
- Cloud M L, Enas G C, Kemp J, Platts-Mills T, Altman L C, Townley R, Tinkelman D, King T, Middleton E, Sheffer A L, McFadden E R, Farlow D S. A specific LTD4/LTE4 receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989; 140: 1336
- Israel E, Rubin P, Kemp J P, Grossman J, Pierson W, Siegel S C, Tinkelman D, Murray J J, Busse W, Segal A T, Fish J, Kaiser H B, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen J M. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059
- Spector S L, Smith L], Glass M. the ACCOLATE Asthma Trialists Group: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618
- Miyamoto T, Takishima T, Makino S, Shida T, Nakajima M. Efficacy of a selective leukotriene C4, D4, E4 antagonist, ONO-1078, on adult patients with bronchial asthma. Igaku no Ayumi 1993; 164: 225, in Japanese
- Alvarez J, Szefler S J. Alternative therapy in severe asthma. J Asthma 1992; 29: 3
- Chand N, Sofia R D. Azelastine—A novel in vivo inhibitor of leukotriene biosynthesis: A possible mechanism of action: A mini review. J Asthma 1995; 32: 227
- Dworski R, Fitzgerald G A, Oates J A, Sheller J R, Workman R, Prakash C. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953
- Hui K P, Barnes N C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062
- Gaddy J N, Margolskee D J, Bush R K, Williams V C, Busse W W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146: 358
- Impens N, Reiss T F, Teahan J A, Desmet M, Rossing T H, Shingo S, Zhang J, Schandevyl W, Verbesselt R, Dupont A G. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis 1993; 147: 1442
- Welch M J, Nelson H S, Paull B R, Smith J A, Feiss G, Tobey R E. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. Ann Allergy 1994; 72: 348